Gene-Edited Beagles Show No Detectable Allergy Protein in First Proof-of-Concept Study

Researchers created two gene-edited beagles, Alfie and Bailey, in September 2024. The animals carry a single-letter DNA change that eliminates the production of Can f 1, the primary dog allergen. According to the study authors, analyses of saliva, hair and dander from both dogs found no detectable Can f 1, and extracts did not provoke an allergic skin response in the single sensitized person who was tested. The dogs have exhibited normal growth and development so far, and the authors report no clinically apparent health abnormalities, while noting that the assessment does not cover every possible long-term effect.

Newsweek

Lead author Matt Walker described the work as a “proof of concept” rather than a finished treatment and emphasized that the goal is a minimal, precise genetic change to address a specific problem. He noted that gene-edited animals fall under Food and Drug Administration oversight, which will evaluate animal health, genomic data and any potential impacts on people or the environment. Walker added that there is no announced commercial availability date for such pets. The study’s authors disclosed financial and ownership interests in Kindred Companion Sciences and funding from Can9 Bioengineering, Inc., and a related patent application has been filed.

Newsweek

Bioethicist Jessica Pierce argued that the technology is “consumer-centered innovation,” raising questions about whether redesigning dogs primarily to solve a human allergy problem is ethically justified. She highlighted broader issues, including the risk of treating companion animals as products and the ongoing shelter-overcrowding crisis, suggesting that biotechnology developments cannot be considered in isolation from these societal contexts.

Newsweek

• Gene-edited subjects: 2 beagles (Alfie and Bailey)

Newsweek

• Allergen testing: No detectable Can f 1 in saliva, hair, or dander; no skin reaction in 1 sensitized human subject

Newsweek

• Health assessment: No clinically apparent abnormalities reported to date

Newsweek

• Regulatory status: Subject to FDA review; no commercial release timeline announced

Newsweek

• Financial disclosures: Authors have interests in Kindred Companion Sciences; research funded by Can9 Bioengineering, Inc.

Newsweek

• “The most realistic applications are likely to involve well-characterized genetic conditions where a specific change could provide a meaningful health or welfare benefit,” — Pets Matt Walker, the study's lead author

Newsweek

• “Our goal is not to redesign dogs, but to make a minimal and precise change that addresses a real problem,” — Pets Matt Walker, the study's lead author

Newsweek

• “In my mind this is consumer-centered innovation,” — Jessica Pierce

Newsweek

• “We do not have a commercial availability date to announce,” — Pets Matt Walker, the study's lead author

Newsweek

• “Gene editing does not necessarily involve making dramatic changes to an animal's genetic code,” — Pets Matt Walker, the study's lead author

Newsweek